Genetech Files ITC Complaint Against Biocon’s Pertuzumab Biosimilar
On 27 February 2026, Genentech filed a complaint at the US International Trade Commission (ITC) alleging that Biocon’s importation of its pertuzumab…
Pearce IP is Australia and New Zealand’s leading life sciences-focused intellectual property law firm.
Supporting life sciences clients from early-stage R&D through to commercial launch and beyond.
pearceIP.law | [email protected] | +61 2 9023 9988 | +64 4 886 1199
Popular articles from this firm
